TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

M. Jasek, L. P. Gondek, N. Bejanyan, R. Tiu, J. Huh, K. S. Theil, C. O'Keefe, M. A. McDevitt, J. P. MacIejewski

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)216-219
Number of pages4
Issue number1
StatePublished - Jan 2010
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this